US equities |
NVDA $186.64 ▲+2.78% MU $690.00 ▲+5.12% AMD $449.04 ▲+11.04% SPCX $134.27 ▲+8.62% AAPL $342.37 ▼-0.52% SNDK $835.06 ▲+3.55% MSFT $530.61 ▼-0.99% TSLA $358.22 ▲+4.23%
FinancialContent

Repare Therapeutics Inc. - Common Shares (NQ:RPTX)

2.650 UNCHANGED
Last Price Updated: 4:00 PM EST, Jan 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Repare Therapeutics Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Roche Terminates Cancer Drug Pact With Repare Therapeutics, Its Second Walkout Within A Month ↗
Repare Therapeutics regains global rights to camonsertib (RP-3500) after terminating collaboration with Roche. $40M milestone achieved. 
Via Benzinga
News headline image
Repare Therapeutics to Regain Global Rights to Camonsertib
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Repare Therapeutics Announces Achievement of $40 Million Roche Clinical Milestone Payment
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Repare Therapeutics Provides Corporate Update and Highlights Anticipated Key 2024 Milestones
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Recap: Repare Therapeutics Q3 Earnings ↗
 
Via Benzinga
News headline image
Wall Street Thinks This Cathie Wood Stock Could Jump by 187% ↗
This small-cap biotech stock holds enormous growth potential. 
Via The Motley Fool
News headline image
Repare Therapeutics and Debiopharm Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Repare Therapeutics Insiders Establish Automatic Securities Disposition Plans
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Repare Therapeutics Unveils Two Programs Expected to Enter Clinical Trials in 2024: RP-1664, an Oral PLK4 Inhibitor, and RP-3467, an Oral Polθ Inhibitor
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Analyst Expectations for Repare Therapeutics's Future ↗
 
Via Benzinga
News headline image
These Biotech Stocks Could Double Your Money, According To Analysts ↗
 
Via Benzinga
News headline image
Repare Therapeutics Provides Business Update and Reports Third Quarter 2023 Financial Results
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Repare Therapeutics to Host Investor and Analyst Conference Call and Webcast
From Repare Therapeutics Inc.
Via Business Wire
News headline image
$2.8M Bet On Repare Therapeutics? Check Out These 4 Penny Stocks Insiders Are Aggressively Buying ↗
The Dow Jones closed higher by over 200 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Topics Stocks
News headline image
12 Health Care Stocks Moving In Monday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Repare Therapeutics to Participate in Two Upcoming Investor Conferences
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Repare Therapeutics Announces Positive Initial Data from Phase 1 MYTHIC Clinical Trial Evaluating Lunresertib Alone and in Combination with Camonsertib
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial Phase 1 MYTHIC Modules 1 and 2 Clinical Data Presented at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Why ParaZero Technologies Shares Are Trading Higher By Over 100%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers ParaZero Technologies Ltd. (NASDAQ: PRZO) shares jumped 106% to $2.3901 after the company announced an Australian regulator approved first commercial drone flights in populated areas and near... 
Via Benzinga
News headline image
Repare Therapeutics to Present Preliminary Phase 1 MYTHIC Module 1 and 2 Data at 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Repare Therapeutics to Participate at the Morgan Stanley 21st Annual Global Healthcare Conference
From Repare Therapeutics Inc.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
Repare Therapeutics Inc. (NASDAQ: RPTX) Near the Top of Equities by Percentage Gain on 8/10
Via Investor Brand Network
News headline image
Repare Therapeutics Provides Business Update and Reports Second Quarter 2023 Financial Results
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For June 9, 2023 ↗
 
Via Benzinga
News headline image
Repare Therapeutics Releases Early Anticancer Activity From Its Monotherapy, Combination Trials ↗
Repare Therapeutics Inc (NASDAQ: RPTX) reported initial proof of concept monotherapy data from its Phase 1 MYTHIC trial evaluating lunresertib (RP-6306) in molecularly selected  
Via Benzinga
News headline image
Repare Therapeutics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Repare Therapeutics Reports Proof of Concept for Lunresertib (RP-6306) in Clinic, Initial Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Insights from Ongoing Combination Trials
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Repare Therapeutics Announces Publication in Nature Medicine Highlighting Clinical Benefit of Camonsertib in Advanced Solid Tumors
From Repare Therapeutics Inc.
Via Business Wire
News headline image
Repare Therapeutics to Host Conference Call and Webcast to Discuss Initial RP-6306 Monotherapy Data from Phase 1 MYTHIC Clinical Trial and Early Combination Trials Insights
From Repare Therapeutics Inc.
Via Business Wire
< Previous 1 2 3 4 5 6 7 8 Next >